Price movement over the last 24 hours
Abeona Therapeutics Inc vs Nerdwallet Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Nerdwallet Inc trades at $9.38 (market cap $625.42M). The key difference: Nerdwallet Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NRDS | |
|---|---|---|
Market Cap | $373.32M | $625.42M |
Sector | Health | Financials |
52-Week High | $7.23 | $15.93 |
52-Week Low | $4.17 | $7.58 |
Enterprise Value | $228.22M | $539.72M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NRDS trades at $9.50, up 0.32% today, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company shows strong fundamental improvement, with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive to $48.7M. Recent quarters have consistently beaten EPS estimates, and analyst consensus is a Buy with a $12.75 target, implying 34% upside. Positive news highlights the company's pivot to higher-margin transactions and resilience amid search headwinds.
The outlook is positive given strong earnings beats, robust cash flow, and attractive valuation multiples like a P/E of 10.19. Key risks include reliance on search traffic, competitive pressures, and projected negative net cash flow in 2026. Institutional sentiment is bullish, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer finance behavior.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →